An observational pilot study in 126 patients with heart failure with preserved ejection fraction (HFpEF) investigated the effects of colchicine on inflammatory markers and symptoms. Patients with elevated levels of IL-6, IL-8, and TNF-α received colchicine at a dose of 0.5 mg daily. After 2 weeks of treatment, IL-8 decreased by -28.65 (95% CI: -54.20 to -11.47, p=0.0010), a 65.5% decrease (95% CI: -82.0% to -45.0%), and IL-6 by -1.925 (95% CI: -4.510 to -0.29, p=0.0010). p=0.0028), i.e. a 30.5% decrease (95% CI: -54.0% to -5.0%). The most significantly elevated markers were IL-8 and IL-6. At 1 month, anxiety (HAMA) decreased by -1 (95% CI: -1.0 to -1.0, p<0.0001), depression (HAMD) by -1 (95% CI: -1.0 to 0.0, p<0.0001) and quality of life (KCCQ) increased by 10 points (p<0.0001). The study suggests that colchicine safely reduces inflammatory markers and improves symptoms in patients with HFpEF.